content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
          -----------------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): March 24, 2005
                                                            --------------
  
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
           Delaware                          000-14879            22-2322400
  ----------------------------     ---------------------------  ----------------
  (State or Other Jurisdiction       (Commission File Number)   (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
      650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  --------------------------------------------------------------------  ----------
            (Address of Principal Executive Offices)                    (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  <PAGE>
  
  
  ITEM 8.01  OTHER EVENTS.
  
       Advanced Magnetics, Inc., the developer of Combidex(R) which is exclusively
  licensed to Cytogen Corporation for marketing in the United States, has informed
  Cytogen that Advanced Magnetics received an approvable letter from the U.S. Food
  and Drug Administration for Combidex.
  
  
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                             CYTOGEN CORPORATION
  
  
  
                                             By:    /s/ William J. Thomas
                                                 ---------------------------------
                                                 William J. Thomas
                                                 Senior Vice President and General
                                                 Counsel
  
  Dated:   March 24, 2005
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_032405.txt", "description": "FORM 8-K MARCH 24, 2005", "secsgml_size_bytes": 3291}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "05700400"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
          -----------------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): March 24, 2005
                                                            --------------
  
                                 CYTOGEN CORPORATION
        --------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
           Delaware                          000-14879            22-2322400
  ----------------------------     ---------------------------  ----------------
  (State or Other Jurisdiction       (Commission File Number)   (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
      650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  --------------------------------------------------------------------  ----------
            (Address of Principal Executive Offices)                    (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 8.01  OTHER EVENTS.
  
       Advanced Magnetics, Inc., the developer of Combidex(R) which is exclusively
  licensed to Cytogen Corporation for marketing in the United States, has informed
  Cytogen that Advanced Magnetics received an approvable letter from the U.S. Food
  and Drug Administration for Combidex.
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                             CYTOGEN CORPORATION
  
                                             By:    /s/ William J. Thomas
                                                 ---------------------------------
                                                 William J. Thomas
                                                 Senior Vice President and General
                                                 Counsel
  
  Dated:   March 24, 2005